Close
  Indian J Med Microbiol
 

Figure 1: A 54-year-old woman with differentiated thyroid cancer underwent ablation with radioiodine therapy. Posttreatment scan revealed just extensive uptake of I-131 in thyroid bed and did not show any remarkable uptake in the rest of the body. As the previous study indicated the Prostate-specific membrane antigen expression in differentiated thyroid cancer,[18],[20]99mTc-prostate-specific membrane antigen scintigraphy was done for disease assessment showing diffuse severe uptake in the lung (a). As mentioned in previous studies,[45],[46] currently, the therapeutic options are limited for patients with metastasized,131I-resistant differentiated thyroid cancer, therefore, in another case,99mTc-prostate-specific membrane antigen scintigraphy was performed in a 40-year-old male with radioiodine refractory differentiated thyroid cancer. The scan showed a diffuse severe uptake of radiotracer in the lung (b). Therefore, such patients can be a candidate for novel therapy with177Lu-prostate-specific membrane antigen

Figure 1: A 54-year-old woman with differentiated thyroid cancer underwent ablation with radioiodine therapy. Posttreatment scan revealed just extensive uptake of I-131 in thyroid bed and did not show any remarkable uptake in the rest of the body. As the previous study indicated the Prostate-specific membrane antigen expression in differentiated thyroid cancer,<sup>[18],[20]</sup><sup>99m</sup>Tc-prostate-specific membrane antigen scintigraphy was done for disease assessment showing diffuse severe uptake in the lung (a). As mentioned in previous studies,<sup>[45],[46]</sup> currently, the therapeutic options are limited for patients with metastasized,<sup>131</sup>I-resistant differentiated thyroid cancer, therefore, in another case,<sup>99m</sup>Tc-prostate-specific membrane antigen scintigraphy was performed in a 40-year-old male with radioiodine refractory differentiated thyroid cancer. The scan showed a diffuse severe uptake of radiotracer in the lung (b). Therefore, such patients can be a candidate for novel therapy with<sup>177</sup>Lu-prostate-specific membrane antigen